Revolver Peptides - antagonising an "undruggable" transcription factor

Revolver TX正在开发基于多肽的新型转录因子抑制剂，这些转录因子以前被认为是难以对付的药物靶点，对癌细胞的增殖至关重要。我们的项目专注于通过进行临床前疗效研究来评估一种能够从DNA中移除转录因子的功能性抑制剂，以验证我们的技术平台。因此，利用工程生物技术，Revolver多肽被集中在对“无法下药”的转录因子进行药物治疗。我们最初的治疗重点是癌症。根据世界卫生组织的数据，癌症是全球主要的死亡原因，2020年有近1000万人死于癌症，预计未来20年新的癌症病例数量将增加70%。在英国，每年新增癌症病例超过36万例，即每天990例。在英国，每两分钟就有一个人被诊断出患有癌症。尽管对研究的历史性投资提高了癌症的存活率，但并不是所有形式的癌症都取得了这样的进展，对于某些癌症来说，长期存活率几十年来没有变化。因此，迫切需要一个强大的平台来改变药物筛选，从而改进现有的治疗方案。在整个制药业，潜在的抗癌新药主导着他们的流水线，至少占目前正在开发的所有药物的三分之一，而且每年都在继续增长。全球近7000种新的癌症产品正在开发中，是第二大治疗领域总和的两倍。我们相信，制药业对差异化早期癌症资产的需求至少在未来五年内将继续增长，而且很可能还会继续增长。在这些前所未有的投资水平的推动下，制药业仍然渴望真正的差异化药物发现计划及其基础平台技术。因此，制药公司继续采用一种战略方法，将创新的研发要求外包给专业合作伙伴，包括对早期治疗产品的许可。这一既定战略的动机是观察到，目前的内部药物管道未能满足发现具有成本效益的新疗法的预期增长需求，而没有外部来源的创新来补充这一需求。Revolver的愿景是成为向制药业提供药物发现解决方案和早期治疗资产的全球市场领先者，将产生Revolver多肽的独特蛋白质-DNA屏幕作为研究工具，使创新的新疗法得以发现。

Revolver Tx is developing novel peptide-based inhibitors of transcription factors, which were previously thought to be intractable drug targets and are critical to the proliferation of cancer cells. Our project is focused on evaluating a functional inhibitor capable of removing transcription factors from DNA by conducting preclinical efficacy studies to validate our technology platform. Consequently, Revolver Peptides are focused on drugging "undruggable" transcription factors by using engineering biology technology. Our initial therapeutic focus is on cancer.According to the World Health Organisation, cancer is a leading cause of death worldwide and accounted for nearly 10 million deaths in 2020, with the number of new cancer cases is expected to rise by 70% over the next two decades. In the UK, there are more than 360,000 new cancer cases every year, which is 990 every day. Every two minutes someone in the UK is diagnosed with cancer. Although historic investment in research has resulted in cancer survival rates improving, not all forms of the disease have seen such progress, and, for some cancers, long-term survival rates have not changed for decades. Consequently, there is an urgent need for a robust platform to transform drug screening, leading to improvements over current treatment options.Across the pharmaceutical industry, potential new cancer drugs dominate their pipeline, comprising at least one third of all drugs currently in development, which has continued to grow each year. Almost 7,000 new cancer products were in development globally, double the total of the next largest therapeutic area. We believe the pharmaceutical industry's appetite for differentiated early-stage cancer assets will continue to grow for at least the next five years and, probably, well beyond.Fed by these unprecedented levels of investment, the pharmaceutical industry remains hungry for truly differentiated drug discovery programmes and their underpinning platform technologies. Consequently, pharmaceutical companies continue to adopt a strategic approach to the outsourcing of innovative R&D requirements to specialist partners by in licensing of early-stage therapeutic products. This established strategy is motivated by the observation that current internal drug pipelines are failing to meet the expected growth demands for discovering cost-effective new therapies without supplementing this with externally sourced innovation. The vision for Revolver is to become a global market leader in providing drug discovery solutions and early-stage therapeutic assets to the pharmaceutical industry by commercially exploiting unique protein-DNA screens generating Revolver Peptides as research tools to enable the discovery of innovative new therapeutics.